Patents by Inventor Thomas E.N. Jonassen

Thomas E.N. Jonassen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8703702
    Abstract: The invention describes peptide analogues of ?-melanocyte-stimulating hormone (?-MSH), which possess an increased efficacy compared to the native ?-MSH peptide. The ?-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to ?-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: April 22, 2014
    Assignee: AbbVie Inc.
    Inventors: Thomas E. N. Jonassen, Soren Nielsen, Jorgen Frokiaer, Bjarne Due Larsen
  • Patent number: 8563508
    Abstract: The invention describes peptide analogues of ?-melanocyte-stimulating hormone (?-MSH), which possess an increased efficacy compared to the native ?-MSH peptide. The ?-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to ?-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: October 22, 2013
    Assignee: AbbVie Inc.
    Inventors: Thomas E. N. Jonassen, Soren Nielsen, Jorgen Frokiaer, Bjarne Due Larsen
  • Publication number: 20130252891
    Abstract: The invention describes peptide analogues of ?-melanocyte-stimulating hormone (?-MSH), which possess an increased efficacy compared to the native ?-MSH peptide. The ?-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to ?-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.
    Type: Application
    Filed: June 3, 2013
    Publication date: September 26, 2013
    Applicant: AbbVie Inc.
    Inventors: Thomas E.N. JONASSEN, Soren NIELSEN, Jorgen FROKIAER, Bjarne Due LARSEN
  • Patent number: 8466104
    Abstract: The invention describes peptide analogues of a-melanocyte-stimulating hormone (a-MSH), which posses an increased efficacy compared to the native ?-MSH peptide. The ?-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to ?-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: June 18, 2013
    Assignee: AbbVie Inc.
    Inventors: Thomas E. N. Jonassen, Soren Nielsen, Jorgen Frokiaer, Bjarne Due Larsen
  • Publication number: 20090069242
    Abstract: The invention describes peptide analogues of a-melanocyte-stimulating hormone (a-MSH), which posses an increased efficacy compared to the native ?-MSH peptide. The ?-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to ?-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.
    Type: Application
    Filed: August 26, 2005
    Publication date: March 12, 2009
    Applicant: ACTION PHARMA A/S
    Inventors: Thomas E.N. Jonassen, Soren Nielsen, Jorgen Frokiaer, Bjarne Due Larsen